Myovant Sciences Submits New Drug Application (NDA) to the FDA for Once-Daily Relugolix Combination Tablet for the Treatment of Women with Uterine Fibroids

NEXT STORY
Ayala Pharmaceuticals to Present at Upcoming Investor Conferences
PREV STORY
Mayo Clinic joins Biomerica’s InFoods® Irritable Bowel Syndrome (“IBS”) Diagnostic-Guided Therapy clinical trial
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Rafael Pharmaceuticals Announces First Patient Enrolled in APOLLO 613 Phase 1/2 Clinical Trial of CPI-613® (Devimistat) in Patients with Relapsed Clear Cell Sarcoma

author_avatar
NASDAQ Market News

At the Meet Novartis Management investor event, Novartis highlights strategy to focus the company and drive sustainable growth

Full pipeline of late stage assets with blockbuster potential Positioned to deliver sales growth ...

author_avatar
NASDAQ Market News

Radiopharmaceuticals Market ($13.81Bn by 2028) Growth Forecast at 9% CAGR During (2021-2028) – COVID-19 Impact and Global Analysis by TheInsightPartners.com

author_avatar
NASDAQ Market News